In Brief: Endosonics
This article was originally published in The Gray Sheet
Endosonics: Intravascular ultrasound products manufacturer plans to commence shipments this month of its WaveWire/WaveMap angioplasty guidewire system, which was cleared in September for use in measuring intracoronary blood pressure ("The Gray Sheet" Sept. 15, In Brief). The device will be marketed through a combination of Endosonics' 32-person direct sales force and Johnson & Johnson's Cordis unit, which is the primary worldwide distributor of the product. One-third of WaveWire/WaveMap sales outside the U.S. currently are generated by direct sales and non-Cordis distributors, Endosonics says...
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.